Ruth Devenyns, Precirix CEO
March 16, 2022 10:45 AM EDT
Financing

Biotech up­start rides the up­surge in ra­dio­phar­ma R&D to $88M round with mar­quee in­vestors

Paul Schloesser

Associate Editor

Bel­gian biotech up­start Pre­cir­ix had raised $40 mil­lion in a Se­ries A from 6 VC back­ers four years ago. Now, all of those in­vestors have …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times